Scientists have identified a decades-old compound as a promising new candidate for the treatment of obesity and related metabolic diseases.
TOFA helps cells burn excess energy without changing food intake or exercise. Image credit: Kravaivan11.
Scientists have seen remarkable results in the treatment of metabolic diseases with the drug GLP-1 over the last five years. It has proven effective in managing obesity, diabetes, and fatty liver disease.
Popular drugs like Ozempic, Wegovy, Mounjaro, and Zepbound containing GLP-1 have shown significant weight loss and blood sugar level management capabilities. However, they come with certain risks such as gastrointestinal side effects and appetite suppression.
Research suggests that a compound called 5-tetradecyloxy-2-furoic acid (TOFA) could offer a new approach to treating obesity and related metabolic disorders without suppressing appetite or reducing muscle mass. When combined with other weight loss drugs like semaglutide and tirzepatide, TOFA has shown even greater weight loss results in mice.
More studies are needed to establish the safety and dosage of TOFA in humans before clinical trials can begin. The potential of TOFA as a complementary treatment to existing appetite suppressants is promising.
The findings of this research are published in the journal scientific progress.
_____
Justin Y. Lee others. 2026. Multifunctional oral small molecules targeting energy and lipid metabolism to treat obesity and related metabolic disorders. scientific progress 12(34);doi: 10.1126/sciadv.aed3119
Source: www.sci.news
